IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN
Small Cell Lung Carcinoma
Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
291 Active assets in the Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
vx-970 National Cancer Institute (NCI) | Phase 2 | BBB |
Adebelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | BBB |
Veliparib Central European Society for Anticancer Drug Research | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 SINGLE-CHAIN VARIABLE FRAGMENT VH-LINKER-VL) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (257->230'),(260->233')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB22841 .KAPPA.-CHAIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →